Actively Recruiting
Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
Led by Xinqiao Hospital of Chongqing · Updated on 2025-07-14
40
Participants Needed
2
Research Sites
208 weeks
Total Duration
On this page
Sponsors
X
Xinqiao Hospital of Chongqing
Lead Sponsor
S
Southwest Hospital, China
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of the study was to determine the efficacy and safety of toripalimab combined with radiotherapy in the treatment of oligometastatic nasopharyngeal carcinoma
CONDITIONS
Official Title
Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed written informed consent and able to follow study procedures
- Age between 18 and 75 years
- Histologically or cytologically confirmed nasopharyngeal carcinoma
- Metastatic nasopharyngeal carcinoma confirmed by pathology or imaging (Clinical stage IVB per 8th AJCC edition)
- Oligometastatic disease confirmed by imaging (up to 5 metastatic lesions in 2 or fewer organs)
- No prior treatment for metastatic nasopharyngeal carcinoma
- Unsuitable or unwilling to receive chemotherapy as judged by investigator
- ECOG Performance Status score of 0 or 1
- Estimated life expectancy of at least 6 months
- At least one measurable lesion per RECIST v1.1
- Adequate organ function verified by recent laboratory tests
You will not qualify if you...
- Allergy to any component of toripalimab
- Active autoimmune disease or history of autoimmune disease likely to relapse (except controlled conditions)
- Any active malignancy within 2 years except specified cured cancers
- Recent use of corticosteroids (≥10 mg prednisone daily) or systemic immunosuppressants
- Uncontrolled diabetes or significant electrolyte abnormalities
- History of interstitial lung disease, non-infectious pneumonia, or severe pulmonary conditions
- Severe infections requiring systemic treatment within 14 days
- HIV infection
- Contraindications to immunotherapy or radiotherapy
- Untreated chronic hepatitis B or active hepatitis C
- Recent major surgery requiring general anesthesia within 28 days
- Previous allogeneic stem cell or organ transplantation
- Significant cardiovascular risks within 6 months prior to enrollment
- Grade 2 peripheral nerve disease per NCI-CTCAE V5.0
- Medical conditions affecting drug administration, safety assessment, or compliance
- Participation in another interventional clinical trial concurrently
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Xinqiao Hospital of Chongqing
Chongqing, Chongqing Municipality, China, 400000
Actively Recruiting
2
the second affiliated hospital of Army medical university
Chongqing, Chongqing Municipality, China, 40037
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here